Clalit drug co-payments to be reduced for patients

February 6, 2012 18:53


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Patient co-payments of 62 prescription medications not included in the basket of medical technologies are being reduced by a total of NIS 24 million by Clalit Health Services, the largest health fund.

The decision to reduce the amount of money paid by the patient was reached by Clalit, Health Ministry Deputy Health Minister Ya’acov Litzman and his (outgoing) deputy director-general in charge of health fund supervision, Dr Yoel Lipschitz.

The ministry said some 150,000 Clalit member will benefit.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

Breaking news
March 22, 2019
Two U.S. service members killed in Afghanistan - statement